$10.02
0.212.14%
At Close: -
$10.02
00.00%
After Hours: Jul 5, 4:00 PM EDT
15 minutes delayed
Amicus Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Amicus Therapeutics using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
FOLD | Amicus Therapeutics | -$0.15 | — | — | — | $94.50M | — | — | — | 08/06/2024 | Get Alert |
FOLD | Amicus Therapeutics | -$0.06 | -$0.07 | -$0.02 | 71.43% | $86.27M | $111.19M | $110.40M | -0.71% | 05/09/2024 | Get Alert |
FOLD | Amicus Therapeutics | -$0.19 | -$0.06 | $0.01 | 116.67% | $88.10M | $114.33M | $115.08M | 0.65% | 02/28/2024 | Get Alert |
FOLD | Amicus Therapeutics | -$0.12 | -$0.08 | -$0.07 | 12.50% | $81.69M | $101.36M | $103.50M | 2.11% | 11/08/2023 | Get Alert |
FOLD | Amicus Therapeutics | -$0.21 | -$0.12 | -$0.15 | -25.00% | $80.73M | $89.87M | $94.50M | 5.16% | 08/08/2023 | Get Alert |
FOLD | Amicus Therapeutics | -$0.30 | -$0.15 | -$0.18 | -20.00% | $78.72M | $83.08M | $86.27M | 3.84% | 05/10/2023 | Get Alert |
FOLD | Amicus Therapeutics | -$0.29 | -$0.13 | -$0.19 | -46.15% | $82.15M | $86.29M | $88.10M | 2.09% | 03/01/2023 | Get Alert |
FOLD | Amicus Therapeutics | -$0.19 | -$0.19 | -$0.12 | 36.84% | $79.55M | $84.22M | $81.69M | -3.00% | 11/07/2022 | Get Alert |
FOLD | Amicus Therapeutics | -$0.19 | -$0.22 | -$0.21 | 4.55% | $77.41M | $85.89M | $80.73M | -6.01% | 08/04/2022 | Get Alert |
FOLD | Amicus Therapeutics | -$0.25 | -$0.25 | -$0.30 | -20.00% | $66.40M | $77.13M | $78.72M | 2.05% | 05/09/2022 | Get Alert |
FOLD | Amicus Therapeutics | -$0.27 | -$0.16 | -$0.29 | -81.25% | $70.57M | $83.28M | $82.15M | -1.35% | 02/24/2022 | Get Alert |
FOLD | Amicus Therapeutics | -$0.22 | -$0.18 | -$0.19 | -5.56% | $67.44M | $80.11M | $79.55M | -0.71% | 11/09/2021 | Get Alert |
FOLD | Amicus Therapeutics | -$0.20 | -$0.22 | -$0.19 | 13.64% | $62.35M | $73.36M | $77.41M | 5.52% | 08/05/2021 | Get Alert |
FOLD | Amicus Therapeutics | -$0.35 | -$0.24 | -$0.25 | -4.17% | $60.52M | $71.65M | $66.40M | -7.32% | 05/10/2021 | Get Alert |
FOLD | Amicus Therapeutics | -$0.35 | -$0.23 | -$0.27 | -17.39% | $55.29M | $70.06M | $70.57M | 0.73% | 03/01/2021 | Get Alert |
FOLD | Amicus Therapeutics | -$0.24 | -$0.22 | -$0.22 | 0.00% | $48.77M | $65.10M | $67.44M | 3.59% | 11/05/2020 | Get Alert |
FOLD | Amicus Therapeutics | -$0.36 | -$0.26 | -$0.20 | 23.08% | $44.13M | $62.38M | $62.35M | -0.04% | 08/10/2020 | Get Alert |
FOLD | Amicus Therapeutics | -$0.39 | -$0.28 | -$0.35 | -25.00% | $34.05M | $57.49M | $60.52M | 5.28% | 05/07/2020 | Get Alert |
FOLD | Amicus Therapeutics | -$0.41 | -$0.27 | -$0.35 | -29.63% | $32.64M | $52.33M | $55.29M | 5.66% | 03/02/2020 | Get Alert |
FOLD | Amicus Therapeutics | -$0.31 | -$0.32 | -$0.24 | 25.00% | $20.60M | $47.66M | $48.77M | 2.32% | 11/11/2019 | Get Alert |
FOLD | Amicus Therapeutics | -$0.33 | -$0.33 | -$0.36 | -9.09% | $21.31M | $41.13M | $44.13M | 7.29% | 08/08/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-09 | $-0.02 | $-0.07 | 71.4 % |
Dec 2023 | 2024-02-28 | $0.01 | $-0.06 | 116.7 % |
Sep 2023 | 2023-11-08 | $-0.07 | $-0.08 | 12.5 % |
Jun 2023 | 2023-08-08 | $-0.15 | $-0.12 | -25.0 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-09 | $110.40M | $111.19M | -0.71 % |
Dec 2023 | 2024-02-28 | $115.08M | $114.34M | 0.65 % |
Sep 2023 | 2023-11-08 | $103.50M | $101.36M | 2.11 % |
Jun 2023 | 2023-08-08 | $94.50M | $89.87M | 5.16 % |
Amicus Therapeutics (FOLD) is scheduled to report earnings on August 6, 2024. The last reported earnings were for reported on May 9, 2024 for Q1.
The Actual EPS was $-0.02, which beat the estimate of $-0.07.
The Actual Revenue was $110.4M, which missed the estimate of $111.2M.
Browse earnings estimates, EPS, and revenue on all stocks.